SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism

Shu Shen1,2†, Jingyuan Zhang1†, Yaohui Fang1†, Sihong Lu3, Jun Wu3, Xin Zheng3* and Fei Deng1,2*

Abstract
Evidence suggests that platelets may directly interact with SARS-CoV-2, raising the concern whether ACE2 receptor plays a role in this interaction. The current study showed that SARS-CoV-2 interacts with both platelets and megakaryocytes despite the limited efficiency. Abundance of the conventional receptor ACE2 and alternative receptors or co-factors for SARS-CoV-2 entry was characterized in platelets from COVID-19 patients and healthy persons as well as human megakaryocytes based on laboratory tests or previously reported RNA-seq data. The results suggest that SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism and may regulate alternative receptor expression associated with COVID-19 coagulation dysfunction.

Keywords: COVID-19, SARS-CoV-2, Platelets, Platelet activation, ACE2, Alternative receptors

To the editor
Associated with coagulative disorders, COVID-19 patients have increased platelet activation and aggregation, and platelet-monocyte aggregation [1–3], which highlights the critical role of platelets in SARS-CoV-2 infection and immunopathology [4]. Consistent with previous reports [1–3], our retrospective survey of plasma samples from a cohort of 62 cases (severe or fatal and moderate COVID-19 patients, Additional file 1: Table S1) showed that COVID-19 was associated with mild thrombocytopenia (platelet count < 150 × 10^9/L) and increased thrombosis (elevated D-dimer levels), and patients had increased platelet activation (elevated sP-selectin and sGPVI levels) and cytokine (PF4 and RANTES) release upon platelet activation (Fig. 1a). Direct interaction of SARS-CoV-2 with human platelets was suggested based on increased P-selectin translocation on platelet surface (Fig. 1b), and elevated levels of GPVI, PF4, and RANTES in platelet culture supernatants (Fig. 1c). However, the characteristics and mechanisms of the direct interaction between SARS-CoV-2 and platelets are not well elucidated, and the role of platelet receptors in the interaction remains to be clarified [4, 5].

SARS-CoV-2 infection in human platelets and its progenitor megakaryocyte cell line MEG-01 in vitro was subsequently characterized. SARS-CoV-2 N expression was observed in some platelets and MEG-01 cells (Fig. 2a). SARS-CoV-2 RNA was detected in both culture supernatant and MEG-01 cells after SARS-CoV-2 incubation and could be maintained with a slight increase until 48 h p.i. (Fig. 2b). This suggests that SARS-CoV-2 may infect and replicate in megakaryocytes despite insufficient efficiency. However, we failed to observe any viral particles in...
MEG-01 cells through electron microscopy, probably because of using insufficient dose of viruses (1 MOI) for incubation, or limited infection in MEG-01 cells, as indicated by IFA images. SARS-CoV-2 RNA copies were lower in platelets (10–10^2 copies/10^3 cells) and culture supernatant (10^3–10^4 copies/mL), which diminished after 12 h (data not shown). Therefore, we speculate that platelets may not support SARS-CoV-2 replication. This echoes recent studies which have shown that SARS-CoV-2 entry in platelets may not be common in COVID-19 patients: SARS-CoV-2 RNA was detected in platelets from a few severe (2/25, 8% [2]; 2/11, 18.2% [6]) and non-severe (9/38, 23.7% [6]) patients and was not detected in platelets from patients (0/24 [7]).

The evidence of direct interaction between SARS-CoV-2 and platelets or megakaryocytes raised the concern whether ACE2 plays a role in the process. The IFA and western blot assays showed a lack of ACE2 expression in both human platelets and megakaryocytes (Fig. 2c, d). The RNA abundance of 14 receptors or co-factors including ACE2 in human platelets and megakaryocytes was subsequently inspected based on RNA-seq data reported in previous studies [2, 8] (Additional file 1: Table S2 and S3). As summarized in Fig. 2e, the abundance order in platelets was: CD147 > GRP78 > KREMEN1 > ADAM17 > cathepsin L > NRP1 > ASGR1 > CD209/L-SIGN > CD301 > CD26 > CD206, but CD209/DC-SIGN, ACE2, and TMPRSS2 were not identified.

Human megakaryocytes had similar receptor profiles, coupled with the detection of CD209/DC-SIGN. We also verified receptor abundance in MEG-01 and human platelets using qRT-PCR. In MEG-01 cells, CD147, GRP78, KREMEN1, cathepsin L, NRP1, and ASGR1 were detected, while in platelets, CD147, GRP78, KREMEN1, and ASGR1 were detected. ACE2 was not detected in MEG-01 cells or platelets (Fig. 2f). These results indicate that SARS-CoV-2 may use receptors other than ACE2 to interact with platelets or megakaryocytes.

Further analysis using the RNA-seq data showed unchanged GRP78, ADAM1, cathepsin L, GRP1, and ASGR1 abundance in platelets between ICU and non-ICU COVID-19 patients and healthy persons and revealed elevated CD147 and KREMEN1 levels and reduced NRP1 levels in patients (Fig. 2g). This was also observed in MEG-01 cells with increased CD147 and KREMEN1 levels and slightly reduced NRP1 levels after SARS-CoV-2 incubation (Fig. 2h). These data suggest that SARS-CoV-2 infection may alter gene transcription in platelets and megakaryocytes, which is similar to DENV infection that markedly changes the platelet and megakaryocyte transcriptome [8].

Owing to their roles in binding to spike protein and facilitating virus entry [9–11], CD147, KREMEN1, and NRP1 triggering of SARS-CoV-2 entry in human platelets and megakaryocytes requires in-depth investigation. Moreover, based on the original functions of CD147 in signaling pathways via cell–cell interactions...
[9] and of NRPI in cardiovascular, neuronal, and immune systems [10], SARS-CoV-2 interaction with platelets is suspected to regulate platelet-mediated immune response [12] and promote coagulation dysfunction in COVID-19 [10].

Abbreviations
COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus; SARS-CoV-2 N: SARS-CoV-2 nucleoprotein; ACE2: Angiotensin-converting enzyme 2; sP-selectin: Soluble P-selectin; sGPVII: Soluble glycoprotein VII; PF4: Platelet factor 4; RANTES: C-C motif chemokine ligand 5; CXCL5; CD147: Baxigin; GRP78: Glucose regulating protein 78; KREMEN1: Kringle containing transmembrane protein 1; ADAM17: A disintegrin and metalloproteinase 17; NRPI: Neurophilin-1; ASGPRI: Asialoglycoprotein receptor-1; CD209/L-SIGN: C-type lectin domain family 4, member M, CLEC4M; CD301: C-type lectin domain containing 10A, CLEC10A; CD26: Dipeptidyl peptidase 4, DPP4; CD209: DC-SIGN: DC-specific intracellular adhesion molecule 3 (ICAM-3)-grabbing non-integrin; TMPRSS2: Transmembrane serine protease 2; DENV: Dengue virus; IFAs: Immunofluorescence assays; qRT-PCR: Quantitative reverse transcription-polymerase chain reaction; MOI: Multiplicity of infection; h p.i.: Hours post-inoculation.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13045-021-01082-6.

Additional file 1. Detailed materials and methods, and supplementary tables and figure.

Acknowledgements
We acknowledge Mr. Ding Gao, Ms. Anna Du, Ms. Juan Min, Ms. Pei Zhang, and Ms. Bichao Xu from the Core Facility and Technical Support Facility of the Wuhan Institute of Virology for their technical assistance. We thank Mr. Jia Wu, Mr. Hao Tang, and Mr. Jun Liu from the team of BSU-3 Laboratory of Wuhan Institute of Virology for their critical support in experimental activities, and Ms. Min Zhou and Mr. Zhong Zhang for their help with cell culture.

Authors’ contributions
SS and DF designed and conceived the project. SS, ZJY, and FYH performed the research, analyzed the data, and wrote the manuscript. LSH, WJ, and ZX performed the qRT-PCR and transduction experiments. LSH, WJ, and SY collected and analyzed the clinical data. All authors have contributed to and approved the manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (U20A20135), the National Program on Key Research Project of China (2018YFE0200402, 2019YFC1200701, and 2020YFC0845801), and the Fundamental Research Funds for the Central Universities (2020kyxgj016).

Availability of data and materials
All data generated or analyzed during this study are included in this published article (and its supplementary information files).

Declarations
Ethics approval and consent to participate
The study protocol was approved by the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology (number: 20200042–02-02).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Hubei Province, Xiaohongshan 44#, Wuchang District, Wuhan City 430071, People’s Republic of China. 2 National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences, 430071 Wuhan, People’s Republic of China. 3 Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Province, Jiefang Avenue 1277#, Jiangnan District, Wuhan City 430022, People’s Republic of China.

Received: 19 February 2021 Accepted: 15 April 2021
Published online: 29 April 2021

References
1. Hottz ED, Azevedo-Quintanilha KG, Palhinha L, Teixeira L, Barreto EA, Pão CR, et al. Platelet activation and platelet-monocyte aggregates formation trigger tissue factor expression in patients with severe COVID-19. Blood. 2020;136:1330–41.
2. Manne BK, Denorome F, Middleton EA, Portier I, Rowley JW, Stubben CJ, et al. Platelet gene expression and function in patients with COVID-19. Blood. 2020;136:1317–29.
3. Middleton EA, He XY, Denorome F, Campbell RA, Ng D, Salvatore SP, et al. Neutrophil extracellular traps (NETs) contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020;136:1169–79.
4. Koupnenova M, Freedman JE. Platelets and COVID-19: Inflammation, hyperactivation and additional questions. Circ Res. 2020;127(1):1419–21.
5. Campbell RA, Bolardi E, Rondina MT. Is there a role for the ACE2 receptor in SARS-CoV-2 interactions with platelets? J Thromb Haemost. 2021;19(1):46–50.
6. Zaid Y, Puhm F, Allaayas I, Naya A, Oudghiri M, Khalil I, et al. Platelets can associate with SARS-CoV-2 RNA and are hyperactivated in COVID-19. Circ Res. 2020;127(1):1404–18.
7. Bury L, Camilloni B, Castronari R, Piselli E, Malvestiti M, Borghi M, et al. Search for SARS-CoV-2 RNA in platelets from COVID-19 patients. Platelets. 2021;32(2):284–7.
8. Campbell RA, Schwartz H, Hottz ED, Rowley JW, Manne BK, Washington AV, et al. Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3. Blood. 2019;133(19):2013–26.
9. Wang K, Chen W, Zhang Z, Deng Y, Lian JQ, Du P, et al. CD147 spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther. 2020;5(1):283.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.